<html>

<head>
   <meta http-equiv="Content-Language" content="en-us">
   <meta name="GENERATOR" content="Microsoft FrontPage 5.0">
   <meta name="ProgId" content="FrontPage.Editor.Document">
   <meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
   <title>DPP - IV Inhibitors</title>
   <style>
      p.MsoNormal {
         mso-style-parent: "";
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText {
         margin-bottom: .0001pt;
         line-height: 150%;
         font-size: 14.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText2 {
         margin-bottom: .0001pt;
         text-align: justify;
         line-height: 150%;
         layout-grid-mode: char;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.Index {
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }
   </style>
</head>

<body>

   <p class="MsoNormal" align="center"><b><u>
            <span style="font-family: Arial">
               <font size="4">The Role of DPP-4 Inhibitors in the<br> Management of Type 2 Diabetes</font>
            </span></u></b></p>
   <p class="MsoNormal" align="center" style="text-align: center"><b><u>
            <span style="font-family: Arial">
               <font size="4">Topic Highlights</font>
            </span></u></b></p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Incretins are gastrointestinal hormones that are beneficial in the control of
            diabetes. They increase the amount of insulin released from the pancreas upon ingestion of food. They also
            inhibit glucagon release.
         </font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b><br></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">DPP-4 is an enzyme that inactivates these hormones which prolongs the life of the gut hormones,
            and thereby controls diabetes.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">DPP-4 inhibitors act by delaying the degradation of vital gastrointestinal hormones that trigger
            pancreatic insulin secretion, at the same time suppressing glucagon secretion.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">DPP-4 inhibitors are significantly more efficacious in the control of the disease than commonly
            prescribed anti-diabetic drugs.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;This visual presentations talks about type 2 diabetes and the potential benefit of
            DPP-4 inhibitors in its treatment.</font>
      </span>
   </p><br>
   <p class="MsoNormal" align="center" style="line-height: 150%">
      <b><u><span style="line-height: 150%; font-family: Arial">
               <font size="4">
                  Transcript</font>
            </span></u></b>
   </p><br>

   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The <a href="https://en.m.wikipedia.org/wiki/pancreas"
               style="color: blue; text-decoration: underline; text-underline: single">human pancreas</a> contains more
            than a million <a href="https://en.m.wikipedia.org/wiki/Islets_of_Langerhans"
               style="color: blue; text-decoration: underline; text-underline: single">Islets of Langerhans</a> in
            varying size, scattered throughout but most profusely in its tail. They comprise about 1% of the pancreatic
            mass. Of the typical cell types numbering about a thousand in these islets, <a
               href="https://en.m.wikipedia.org/wiki/Beta_cell"
               style="color: blue; text-decoration: underline; text-underline: single">'-cells</a> make up about 80% and
            '-cells making up most of the remaining. Insulin that exerts critical control over <a
               href="https://en.m.wikipedia.org/wiki/carbohydrate"
               style="color: blue; text-decoration: underline; text-underline: single">carbohydrate</a>, <a
               href="https://en.m.wikipedia.org/wiki/fat"
               style="color: blue; text-decoration: underline; text-underline: single">fat</a> and <a
               href="https://en.m.wikipedia.org/wiki/protein"
               style="color: blue; text-decoration: underline; text-underline: single">protein</a> metabolism is
            produced in these '-cells while the <a href="https://en.m.wikipedia.org/wiki/Alpha_cell"
               style="color: blue; text-decoration: underline; text-underline: single">Alpha-cells</a> secrete <a
               href="https://en.m.wikipedia.org/wiki/glucagons"
               style="color: blue; text-decoration: underline; text-underline: single">glucagons</a>.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">There is a close correlation between <a href="https://en.m.wikipedia.org/wiki/glucose_metabolism"
               style="color: blue; text-decoration: underline; text-underline: single">glucose metabolism</a> and <a
               href="https://en.m.wikipedia.org/wiki/insulin"
               style="color: blue; text-decoration: underline; text-underline: single">insulin</a> secretion. Insulin
            secretion is released directly into the <a href="https://en.m.wikipedia.org/wiki/portal_vein"
               style="color: blue; text-decoration: underline; text-underline: single">portal vein</a> and responds
            precisely to small changes in glucose concentration. Glucose levels in normal individuals are in the range
            of 70 to 150 mg/dL. The release of insulin from '-cells is not only due to the metabolic signals initiated
            by physiologic levels of glucose, the secretion is also regulated and significantly enhanced by other
            physiologic signals by <a href="https://en.m.wikipedia.org/wiki/amino_acids"
               style="color: blue; text-decoration: underline; text-underline: single">amino acids</a>
            and <a href="https://en.m.wikipedia.org/wiki/gut_hormones"
               style="color: blue; text-decoration: underline; text-underline: single">gut hormones</a> during ingestion
            of food. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Type_2_Diabetes"
               style="color: blue; text-decoration: underline; text-underline: single">Type 2 Diabetes</a> (Diabetes
            Mellitus) occurs as a result of metabolic dysfunction. Peripheral insulin resistance in <a
               href="https://en.m.wikipedia.org/wiki/skeletal_muscle "
               style="color: blue; text-decoration: underline; text-underline: single">skeletal muscle </a>
            and <a href="https://en.m.wikipedia.org/wiki/adipose_tissue"
               style="color: blue; text-decoration: underline; text-underline: single">adipose tissue</a>, and impaired
            pancreatic '-cell function, combination of which leads to elevated plasma glucose levels characterizes type
            2 diabetes.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"> Inception of <a href="https://en.m.wikipedia.org/wiki/hyperglycemia"
               style="color: blue; text-decoration: underline; text-underline: single">hyperglycemia</a> caused by a
            deficiency in insulin secretion is usually the first symptom of type 2 diabetes. This is often seen in
            conjunction with conditions such as <a href="https://en.m.wikipedia.org/wiki/dyslipidemia"
               style="color: blue; text-decoration: underline; text-underline: single">dyslipidemia</a>, abnormalities
            in carbohydrates, fat, and protein metabolism, resulting in weight gain, and an elevation in blood pressure.
            Type 2 Diabetes therefore, is most frequently associated with obesity, elevated plasma free fatty acids, <a
               href="https://en.m.wikipedia.org/wiki/triglycerides"
               style="color: blue; text-decoration: underline; text-underline: single">triglycerides</a>, and
            intracellular <a href="https://en.m.wikipedia.org/wiki/lipid"
               style="color: blue; text-decoration: underline; text-underline: single">lipid</a> deposition.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Over time these dysfunctions can cause irreversible damage to the <a
               href="https://en.m.wikipedia.org/wiki/kidneys"
               style="color: blue; text-decoration: underline; text-underline: single">kidneys</a>, <a
               href="https://en.m.wikipedia.org/wiki/eyes"
               style="color: blue; text-decoration: underline; text-underline: single">eyes</a>, <a
               href="https://en.m.wikipedia.org/wiki/heart"
               style="color: blue; text-decoration: underline; text-underline: single">heart</a>, <a
               href="https://en.m.wikipedia.org/wiki/blood_vessels"
               style="color: blue; text-decoration: underline; text-underline: single">blood vessels</a>, and <a
               href="https://en.m.wikipedia.org/wiki/nerves"
               style="color: blue; text-decoration: underline; text-underline: single">nerves</a>. This damage can lead
            to blindness, vascular clotting, <a href="https://en.m.wikipedia.org/wiki/myocardial_infarction"
               style="color: blue; text-decoration: underline; text-underline: single">myocardial infarction</a>, <a
               href="https://en.m.wikipedia.org/wiki/stroke"
               style="color: blue; text-decoration: underline; text-underline: single">stroke</a>, amputation and even
            death. Many of the current therapies fail to tackle the underlying pathophysiology of diabetes, and are
            consequently ineffective at restoring normal control of glucose metabolism. Ultimately they do not impact
            the disease's progression rate. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The body's glucose absorption is accomplished by insulin produced in the '-cells in the
            pancreatic islets of Langerhans. The gradual development of insulin resistance and the resulting impaired
            glucose tolerance leads to type 2 diabetes. Initially, the islets are able to respond to the increased
            demand of insulin secretion to maintain the normoglycemia. As the disease progresses however, increased
            demand of both the synthesis and secretion of insulin ultimately leads to '-cell dysfunction.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Insulin response to glucose is amplified when delivered orally as opposed to glucose
            administered intravenously. <a href="https://en.m.wikipedia.org/wiki/Peptide_hormones"
               style="color: blue; text-decoration: underline; text-underline: single">Peptide hormones</a> called <a
               href="https://en.m.wikipedia.org/wiki/incretins"
               style="color: blue; text-decoration: underline; text-underline: single">incretins</a> are released from
            the intestine that enhances insulin secretion from the pancreas. Investigations have shown that incretins
            play multiple roles in metabolic homeostasis following nutrient absorption. They enhance glucose-stimulated
            insulin secretion from the pancreas as well as regulate the rate of delivery of nutrients such as glucose
            into circulation.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Incretins produced in small glands in the intestinal wall, called the <a
               href="https://en.m.wikipedia.org/wiki/Crypts_of_Lieberk%C3%BChn"
               style="color: blue; text-decoration: underline; text-underline: single">crypts of Lieberk'hn</a> (these
            glands are present in the mucous membrane open into the intestine) and the pancreas, regulate the rate at
            which nutrients transit the gastrointestinal tract and thereby regulate the rate of delivery of nutrients
            such as glucose into circulation. The incretins have a powerful effect on gastrointestinal motility,
            particularly gastric emptying, thereby decreasing the rate of glucose absorption after a carbohydrate-rich
            meal. In the brain, <a href="https://en.m.wikipedia.org/wiki/GLP-1"
               style="color: blue; text-decoration: underline; text-underline: single">GLP-1</a> decreases food and
            fluid intake. Leptin-induced appetite suppression is in part mediated by GLP-1. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The incretin effect is blunted in individuals with type 2 diabetes, and this appears to
            contribute to glucose intolerance. The incretin defects in patients with type 2 diabetes are due to impaired
            secretion of insulin, accelerated metabolism of the incretin hormones, and the effect of the hormones being
            compromised.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The two predominant incretins areglucagon-like peptide (GLP)-1 and <a
               href="https://en.m.wikipedia.org/wiki/Glucose-dependent_insulinotropic_peptide"
               style="color: blue; text-decoration: underline; text-underline: single">glucose-dependent insulinotropic
               peptide</a> (GIP). </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Glucose-dependent insulinotropic peptide (GIP), also known as gastric inhibitory polypeptide, is
            a 42 amino acid peptide hormone synthesized in and secreted from K-cells in the intestinal epithelium, the
            majority of which are located in the proximal duodenum. GIP secretion is primarily regulated by nutrients,
            especially fats. Although the primary action of GIP is the stimulation of glucose-dependent insulin
            secretion, the physiological significance of GIP action in the adipocyte is less well defined. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Glucagon-like peptide GLP-1 is produced in <a
               href="https://en.m.wikipedia.org/wiki/Enteroendocrine_cell"
               style="color: blue; text-decoration: underline; text-underline: single">enteroendocrine L-cells</a> in
            the <a href="https://en.m.wikipedia.org/wiki/Ileum"
               style="color: blue; text-decoration: underline; text-underline: single">distal ileum</a> and colon in
            response to oral intake of nutrients. Basal plasma levels of intact GLP-1 in humans is 5'10 picomols or pM
            and can increase to approximately 50 pM postprandially. This secretion is regulated by several intracellular
            signals. Experiments have demonstrated that the secretion is controlled by nutrients, neural and endocrine
            factors. The first phase of GLP-1 release is observed within 10 to 15 minutes, and direct nutrient contact
            induces the second phase of the secretion in 30 to 60 minutes. The <a
               href="https://en.m.wikipedia.org/wiki/Vagus_nerve"
               style="color: blue; text-decoration: underline; text-underline: single">vagus nerve</a> plays an
            important role in mediating the rapid release of this hormone from the L-cells in response to nutrient
            ingestion. The neuropeptide GRP stimulates GLP-1secretion in humans. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"> GLP-1 is secreted from intestinal endocrine cells in two principal molecular forms, as GLP-1
            (7-36) amide and GLP-1 (7-37). Studies have shown that postprandial levels of GLP-1 are significantly
            decreased in diabetic patients. The impaired secretion is a consequence rather than a cause of diabetes.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">These peptides stimulate insulin secretion, and, unlike other insulinotropic agents, they do so
            in a glucose-dependent manner. While the insulinotropic action of GLP-1 is especially well preserved, the
            exogenous GIP is comparatively less effective than GLP-1 at stimulating insulin secretion in type 2
            diabetics. Also, no correlations between metabolic parameters and GIP responses have been established in
            type 2 diabetes patients.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">However, significant impairment of the secretion of GLP-1 has been observed in type 2 diabetes
            patients, and, the impairment was found to be related to impaired '-cell function.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Research has shown that removal of the first six amino acids results in a shorter version of the
            GLP-1 molecule with substantially enhanced biological activity. The majority of circulating biologically
            active GLP-1 is found in the GLP-1(7-36) amide form. The structure of GLP-1 (as also GIP and GLP-2) reveals
            a highly conserved <a href="https://en.m.wikipedia.org/wiki/alanine"
               style="color: blue; text-decoration: underline; text-underline: single">alanine</a> at position two,
            rendering this peptide ideal putative substrate for the <a
               href="https://en.m.wikipedia.org/wiki/aminopeptidase"
               style="color: blue; text-decoration: underline; text-underline: single">aminopeptidase</a>, <a
               href="https://en.m.wikipedia.org/wiki/Dipeptidyl_peptidase-4"
               style="color: blue; text-decoration: underline; text-underline: single">dipeptidyl peptidase-IV</a>
            (DPP-IV). (The N-terminal region of GLP-1 has the second amino acid residue alanine, which makes it a prey
            for DPP-IV digestion.)</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The postprandial release of the hormone GLP-1 from L-cells in the intestine exerts biological
            actions that contribute to its ability to lower glucose, including inhibition of gastric motility and
            gastric acid secretions thereby reducing meal-associated increases in glycemic excursion. It suppresses
            glucagon secretion in the pancreatic Alpha-cells and suppresses food intake in both diabetic and
            non-diabetic individuals by slowing down digestion and decreasing appetite.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The biological activities of GLP-1 include stimulation of glucose-dependent insulin secretion
            and insulin biosynthesis, inhibition of glucagon secretion and gastric emptying, and inhibition of food. The
            stimulatory and inhibitory effects of GLP-1 on insulin and glucagon levels, respectively, are glucose
            dependent. Thus GLP-1 does not stimulate insulin secretion or inhibit glucagon secretion in conditions of <a
               href="https://en.m.wikipedia.org/wiki/hypoglycemia"
               style="color: blue; text-decoration: underline; text-underline: single">hypoglycemia</a>. In animal
            studies it has been seen that GLP-1 induces islet cell neogenesis and proliferation.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">GLP-1 has the potential to preserve or enhance '-cell function in type 2 diabetes due to its
            ability to stimulate '-cell proliferation and neogenesis and inhibit apoptosis. In the light of these
            beneficial actions, GLP-1 is viewed as a potential therapeutic agent for the treatment of type 2 diabetes.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The action of GLP-1 is essential for maintaining normal glucose homeostasis as disruption of
            their biological activity leads to impaired glucose tolerance. The major therapeutic drawback with GLP-1 is
            its very short half-life of less than two minutes following exogenous administration, since it is rapidly
            inactivated by the enzyme DPP-IV.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">DPP-IV is a membrane-associated peptidase of 766 amino acids serine protease that is anchored to
            the surface of cells or as a circulating soluble form in
            <a href="https://en.m.wikipedia.org/wiki/plasma"
               style="color: blue; text-decoration: underline; text-underline: single">plasma</a>. It is ubiquitously
            expressed in increased levels in the kidney and in lesser concentration in numerous tissues including the
            liver, pancreas, <a href="https://en.m.wikipedia.org/wiki/placenta"
               style="color: blue; text-decoration: underline; text-underline: single">placenta</a>, <a
               href="https://en.m.wikipedia.org/wiki/thymus"
               style="color: blue; text-decoration: underline; text-underline: single">thymus</a>, <a
               href="https://en.m.wikipedia.org/wiki/spleen"
               style="color: blue; text-decoration: underline; text-underline: single">spleen</a>, <a
               href="https://en.m.wikipedia.org/wiki/Epithelium"
               style="color: blue; text-decoration: underline; text-underline: single">epithelium cells</a>, vascular <a
               href="https://en.m.wikipedia.org/wiki/endoplasm"
               style="color: blue; text-decoration: underline; text-underline: single">endoplasm</a>, and <a
               href="https://en.m.wikipedia.org/wiki/lymphoid "
               style="color: blue; text-decoration: underline; text-underline: single">lymphoid </a> and <a
               href="https://en.m.wikipedia.org/wiki/Myeloid_cells"
               style="color: blue; text-decoration: underline; text-underline: single">myeloid cells</a>, and, as a
            soluble circulating form in plasma, adjacent to the sites of GLP-1 release.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">As a membrane spanning protein, DPP-IV has two distinct mechanisms of action ' intracellular
            signaling properties independent of its enzymatic function, and the other, in its enzymatic function, DPP-IV
            prefers substrates with an amino-terminal proline or alanine at position two. DPP-IV specifically cleaves
            dipeptides from the amino terminus of <a href="https://en.m.wikipedia.org/wiki/oligopeptides"
               style="color: blue; text-decoration: underline; text-underline: single">oligopeptides</a> or proteins
            that contain alanine or proline in the penultimate position (it exhibits postproline or alanine peptidase
            activity), thereby generating biologically inactive peptides. (It works by cleaving the N-terminal region of
            two amino acids X-proline or X-alanine.) </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Since GLP-1 has an alanine residue at position two, it is a substrate for DPP-IV. DPP-IV
            degrades GLP-1 by causing it to give an inactive amide. An amine at position two is absolutely essential for
            inhibition. GLP-1 is rapidly degraded to GLP-1-(9-36)NH2 within 30 minutes of its entering the DPP-IV
            containing blood vessels that drain the intestinal mucosa. The primary route for clearance of GLP-1 is the
            kidney.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Preventing the degradation of native GLP-1 by inhibiting the activity of the DPP-IV enzyme has
            emerged as a therapeutic strategy for enhancing endogenous GLP-1 action. DPP-IV inhibitors can prevent the
            rapid degradation of incretin hormones thereby resulting in postprandial increase in levels of biologically
            active and intact GLP-1. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">DPP-IV inhibitors are orally administered drugs, and work by blocking GLP-1 degradation to keep
            its concentration for a longer period of time. Thus by enhancing endogenous incretin action, DPP-IV
            inhibitors are able to lower blood glucose in a glucose-dependent manner and enhance beta-cell mass by
            promoting proliferation, neogenesis, and survival. They also promote satiety, thereby reducing food intake
            and, subsequently, body weight.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Many DPP-IV inhibitors are now being examined to mitigate the progression of insulin resistance
            that occurs over time in diabetic patients. Several DPP-IV inhibitors such as <a
               href="https://en.m.wikipedia.org/wiki/vildagliptin"
               style="color: blue; text-decoration: underline; text-underline: single">vildagliptin</a>, <a
               href="https://en.m.wikipedia.org/wiki/sitagliptin"
               style="color: blue; text-decoration: underline; text-underline: single">sitagliptin</a>, and <a
               href="https://en.m.wikipedia.org/wiki/saxagliptin"
               style="color: blue; text-decoration: underline; text-underline: single">saxagliptin</a> have been part of
            clinical trials. The inhibitors of DPP-IV have advantages over the GLP-1 analogs in that they are orally
            available and relatively free from side effects.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Selectivity, binding, pharmacokinetic profiles, drug interactions and pharmacodynamic profiles
            are important factors that need to be considered in choosing a suitable DPP-IV inhibitor. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Recent studies have shown that vildagliptin appears to be safe and efficacious as monotherapy in
            type 2 diabetic patients, particularly in those with higher baseline A1Cs. Vildagliptin may contribute to
            the slowing or stopping disease progression. Several clinical trials have demonstrated improved glycemic
            control with the addition of vildagliptin to a variety of agents, including <a
               href="https://en.m.wikipedia.org/wiki/sulfonylureas"
               style="color: blue; text-decoration: underline; text-underline: single">sulfonylureas</a>, <a
               href="https://en.m.wikipedia.org/wiki/metformin"
               style="color: blue; text-decoration: underline; text-underline: single">metformin</a>, <a
               href="https://en.m.wikipedia.org/wiki/thiazolidinediones"
               style="color: blue; text-decoration: underline; text-underline: single">thiazolidinediones</a>, and
            insulin. Researchers believe that vildagliptin is generally safe and well tolerated, with a side-effect
            profile similar to that of placebo, either alone or in combination with other agents.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Sitagliptin is an orally active and selective inhibitor of the DPP-IV enzyme. Clinical data
            indicate that patients treated with sitagliptin for 24 weeks at doses of 100 or 200-mg a day showed
            reductions of <a href="https://en.m.wikipedia.org/wiki/HbA1c"
               style="color: blue; text-decoration: underline; text-underline: single">HbA1c</a> and improved beta-cell
            function and no change in body weight. When administered with metformin or <a
               href="https://en.m.wikipedia.org/wiki/glitazones"
               style="color: blue; text-decoration: underline; text-underline: single">glitazones</a>, sitagliptin has a
            complementary effect. When taken with either metformin or thiazolidinediones there resulted a significant
            reduction in A1c and fasting glucose at 24 weeks which led to a greater proportion of patients achieving A1c
            less than 7% and improved beta cell function. Sitagliptin has been well tolerated by most patients. But some
            people have experienced adverse effects such as respiratory tract infection, diarrhea, headache and joint
            pain.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">In October 2006 the FDA approved sitagliptin phosphate tablets for use with diet and exercise to
            improve glycemic control in adult patients with type 2 diabetes mellitus. The tablets are available in 25-,
            50-, and 100-mg strengths. Sitagliptin can be used alone or in combination with metformin or <a
               href="https://en.m.wikipedia.org/wiki/peroxisome"
               style="color: blue; text-decoration: underline; text-underline: single">peroxisome</a>
            proliferators-activated receptor gamma agonists when treatment with either drug alone provides inadequate
            glucose control. Other DPP inhibitors are part of clinical trials while the FDA has accepted drugs such as
            vildagliptin for review.</font>
      </span>
   </p><br><br>

   <center>
      <div id="google_translate_element"></div>
   </center>
   

   

<script src="https://kit.fontawesome.com/a7d3f41661.js" crossorigin="anonymous"></script>
</body>

</html>